NASDAQ · Key Statistics

InMed Pharmaceuticals Inc. (INM) P/E Ratio, ROE & Key Statistics

$15.56 NASDAQ: INM Market Cap $8.55M

Data as of Nov 9, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for InMed Pharmaceuticals Inc. (INM), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-0.38
P/B ratioShare price divided by book value per share.5.42
P/S ratioMarket value divided by annual revenue.0.63

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.30.44%
Operating marginRevenue left after operating costs.-2.47%
Net marginRevenue left after every cost, including tax and interest.-0.61%
Return on equityProfit as a percentage of shareholders’ equity.-134.73%
Return on assetsProfit as a percentage of total assets.-414.54%
Return on capital employedOperating profit against the capital the business uses.-995.44%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.6.00
Debt to equityTotal borrowings against shareholders’ equity.0.00
Interest coverageHow many times operating profit covers the interest bill.-496.36

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$3.12
Market capitalisationShare price times shares outstanding.$8.55M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$7.23M

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

InMed Pharmaceuticals Inc. (INM) statistics — frequently asked questions

What is InMed Pharmaceuticals Inc.'s P/E ratio?

InMed Pharmaceuticals Inc. (INM) trades on a price-to-earnings ratio of -0.38. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is InMed Pharmaceuticals Inc.'s return on equity?

InMed Pharmaceuticals Inc. (INM) reports a return on equity of -134.73%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does InMed Pharmaceuticals Inc. carry?

InMed Pharmaceuticals Inc. (INM) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.

What is InMed Pharmaceuticals Inc.'s profit margin?

InMed Pharmaceuticals Inc. (INM) keeps -0.61% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.